TP53 and glioblastoma: In the mesenchymal subtype, TP53, EGFR and ATRX mutations were detected in 20 (56%), 10 (28%) and 3 (8%) out of 36 mesenchymal primary GBM respectively, and 70%, 10% and 30% of 10 mesenchymal recurrent glioblastomas.